Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Halozyme Therapeutics in a note issued to investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger anticipates that the biopharmaceutical company will post earnings per share of $0.93 for the quarter. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Leerink Partnrs also issued estimates for Halozyme Therapeutics’ Q2 2025 earnings at $1.04 EPS, Q3 2025 earnings at $1.41 EPS and FY2029 earnings at $8.16 EPS.
Other equities analysts have also issued research reports about the company. Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday. HC Wainwright boosted their target price on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Finally, JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $60.89.
Halozyme Therapeutics Stock Performance
NASDAQ HALO opened at $54.51 on Tuesday. The stock has a 50-day simple moving average of $49.83 and a two-hundred day simple moving average of $54.06. The firm has a market capitalization of $6.94 billion, a P/E ratio of 18.05, a PEG ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.
Insider Buying and Selling
In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.40% of the company’s stock.
Institutional Investors Weigh In On Halozyme Therapeutics
Several hedge funds have recently made changes to their positions in the business. RPg Family Wealth Advisory LLC purchased a new position in Halozyme Therapeutics during the third quarter worth about $1,886,000. Segall Bryant & Hamill LLC grew its position in shares of Halozyme Therapeutics by 16.3% in the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after purchasing an additional 49,856 shares during the last quarter. Retirement Systems of Alabama grew its position in shares of Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after purchasing an additional 74,173 shares during the last quarter. Creative Planning boosted its position in Halozyme Therapeutics by 43.2% during the second quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock worth $1,953,000 after acquiring an additional 11,249 shares during the last quarter. Finally, South Street Advisors LLC acquired a new stake in Halozyme Therapeutics during the third quarter worth approximately $9,812,000. Institutional investors and hedge funds own 97.79% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Further Reading
- Five stocks we like better than Halozyme Therapeutics
- Canada Bond Market Holiday: How to Invest and Trade
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Insider Trades May Not Tell You What You Think
- How Do Stock Buybacks Affect Shareholders?
- What Are the FAANG Stocks and Are They Good Investments?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.